Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, reposted from World Federation of Hemophilia on LinkedIn:
”I’m proud to share this important milestone: Takeda has renewed its 5-year agreement with the WFH and WFH_USA—furthering our support for the WFH Humanitarian Aid Program!
Together with other partners, we are working to expand access, drive equity, and change lives for people living with inherited bleeding disorders globally.”
Quoting World Federation of Hemophilia‘s post:
”The WFH and WFH USA are pleased to announce that Takeda has signed a 5-year agreement renewal with the WFH Humanitarian Aid Program from 2026 to 2030!
The agreement is for the donation of treatment product, as well as a financial commitment to cover it’s handling, storage and shipping. Learn more.”
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 16:48Khusboo Kumari: Laboratory Skills in Hematology
-
Jun 23, 2026, 16:45Advancing Sickle Cell Disease Research Through Community Support – ASH
-
Jun 23, 2026, 16:35Which Thrombophilia Tests Really Matter? – ICHCC
-
Jun 23, 2026, 16:26Ifeanyichukwu Ifechidere: A Prolonged APTT Is Not Always a Bleeding Disorder
-
Jun 23, 2026, 15:36Arun V. J.: Transforming Transfusion Medicine Through Leadership Development
-
Jun 23, 2026, 15:32Wolfgang Miesbach: Liver Organoids Advance the Future of AAV Gene Therapy Safety Testing
-
Jun 23, 2026, 15:27Shadi Tabibian: A New Era in von Willebrand Disease Treatment
-
Jun 23, 2026, 15:13Ibré Gallardo: Shifting Paradigms in AFIB Therapeutics
-
Jun 23, 2026, 14:26James Crowley: The Hidden Burden of Atrial Fibrillation